Brief report: A phase II study of sunitinib in malignant pleural mesothelioma. the NCIC clinical trials group

Journal of Thoracic Oncology

Volumn 6, Issue 11, 2011, Pages 1950-1954

  Laurie, Scott A ^a   Gupta, Ashish ^a   Chu, Quincy ^a   Lee, Christopher W ^a   Morzycki, Wojciech ^a   Feld, Ronald ^a   Foo, Alison H ^a   Seely, Jean ^a   Goffin, John R ^a   Laberge, Francis ^a   Murray, Nevin ^a   Rao, Sanjay ^a   Nicholas, Garth ^a   Laskin, Janessa ^a   Reiman, Tony ^a   Sauciuc, Delia ^a   Seymour, Lesley ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Angiogenesis inhibitor; Mesothelioma; Phase II; Systemic therapy

Indexed keywords

CISPLATIN; SUNITINIB;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; BLOOD TOXICITY; CANCER CONTROL; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EMBOLISM; EPISTAXIS; ESOPHAGITIS; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GENITAL EDEMA; HAND FOOT SYNDROME; HEADACHE; HEART LEFT VENTRICLE FAILURE; HEARTBURN; HUMAN; HYPERTENSION; INFECTION; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RESPIRATORY TRACT HEMORRHAGE; REVIEW; SYSTOLIC DYSFUNCTION; TASTE DISORDER; THORAX PAIN; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; VOMITING;

EID: 80054897151     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182333df5     Document Type: Article

References (15)

1. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21: 2636-2644. (Pubitemid 46606305)
2. van Meerbeeck J, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organization for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005;23:6881-6889.
3. Karrison T, Kindler HL, Gandara DR, et al. Final analysis of a multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM). J Clin Oncol 2007; 25(Suppl 18):abstract 7526.
4. Ohta Y, Sridhar V, Bright RK, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumors. Br J Cancer 1999;81:54-61. (Pubitemid 29415491)
5. Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 2001;193:468-475. (Pubitemid 32266815)
6. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004;15:257-260. (Pubitemid 38262625)
7. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10. (Pubitemid 19099520)
8. Curran D, Shroud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer Experience. J Clin Oncol 1998;16:145-152. (Pubitemid 28041592)
9. Dubey S, Janne PA, Krug L, et al. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thoracic Oncol 2010;5:1655-1661.
10. Nowak AK, Millard M, Francis RJ, et al. Final results of a phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM). J Clin Oncol 2010;28(Suppl 15):abstract 7036.
11. Garland LL, Rankin C, Gandara DR, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 2007;25:2406-2413. (Pubitemid 46999211)
12. Jassem J, Rameau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008;26:1698-1704.
13. Tsao AS, Garland LL, Redman M, et al. A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria. J Thor Oncol 2011; 6:598-601.
14. Wheatley-Price P, Yang B, Patsies D, et al. Soluble mesothelin-related peptide and osteopontin as markers of response in malignant pleural mesothelioma. J Clin Oncol 2010;28:3316-3322.
15. 18 F-FDG PET scans. J Nuclear Med 2007;48:1449-1458. (Pubitemid 47397395)